Current prostate cancer genetic testing capabilities and considerations.
Current prostate cancer genetic testing capabilities and considerations. Can J Urol. 2019 Oct;26(5S2):38-39 Authors: Pilarski R Abstract With the advent of next-generation sequencing technologies, genetic testing of prostate cancer patients is now typically done using multi-gene panels. These vary from targeted disease-specific panels to comprehensive (pan-cancer) panels, with advantages and disadvantages for each. This paper reviews a number of issues raised in choosing the best panels and labs to use, and issues presented by the increasing availability of direct-to-consumer testing. PMID: 31629427 [PubMed - in process]
Condition: Prostate Cancer Interventions: Drug: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots; Diagnostic Test: PET/MRI; Other: Blood and urine sampling; Procedure: laparoscopic radical prostatectomy and bilateral pelvic LN dissection Sponsors: Memorial Sloan Kettering Cancer Center; Elucida Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Prostate Cancer; Obesity Intervention: Procedure: Robotic Radical Prostatectomy Sponsors: Imperial College London; Imperial College Healthcare NHS Trust; Experimental Cancer Medicine Centres Recruiting
Scientists hope the new technique, which limits this damage, will be available on the NHS within five years. Each year around 47,000 British men are diagnosed with prostate cancer.
(University of Texas M. D. Anderson Cancer Center) Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of Texas MD Anderson Cancer Center found men who seek treatment at a multidisciplinary (MultiD) prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines.
Authors: Demers AA, Brenner DR, Smith L, Shaw A Abstract Examining incidence trends of all cancers combined in order to understand cancer trends can be misleading, as patterns can vary across individual cancer types. This paper highlights findings on trends over time from Canadian Cancer Statistics 2019, as measured by the annual percent change (APC) of age-standardized incidence rates. Among the results were a recent increase in thyroid cancer in males (APC: 6.4%, 1997-2015), as well as decreases in prostate cancer (APC: -9.1%, 2011-2015) and cervical cancer (APC: -3.3%, 2010-2015). PMID: 31729314 [PubMed - in process]
Promoting prostate HDR in US would not be bad. scarbrtj said: In theory based on this chart could single fraction prostate HDR pay $23K global? If so look out for a prostate HDR renaissance in the US. CMS is, wittingly or unwittingly, massively incentivizing (and disincentivizing) certain treatment paradigms with this new model. For better or worse! Click to expand...
AbstractBackgroundClaudin-1 is a membrane-tight junction protein and important for the sealing of the paracellular cleft in epithelial and endothelial cells. Differential expression of Claudin-1 is linked to disease outcome in various cancers.Material and methodsTo evaluate the potential relevance of Claudin-1 expression in prostate cancer, a tissue microarray containing samples of 17,747 tumors with annotated clinico-pathological and molecular data was immunohistochemically analyzed for Claudin-1 expression.ResultsIn normal prostate, glandular cells were always Claudin-1-negative while there was a strong staining of gland...
Objective: To investigate the relationship between the new International Society of Urological Pathology (ISUP) grading system, biochemical recurrence (BCR), clinical progression (CP) and cancer related death (CRD) after open radical prostatectomy (RP) and determine whether the 2014 ISUP grading system influences the concept of high-risk prostate cancer (HRPCa).Patients and Methods: A total of 1,754 men who underwent RP from 2005 to 2017 were identified from a database at a single tertiary institution. Histopathology reports were reassessed according to the 2014 ISUP grading system. All preoperative, pathological, and clin...
PROSTATE cancer is the most common type of cancer in men in the UK, and because there ’s currently no cure, it’s important to be aware of the risks for developing the disease. According to studies, how you sleep can increase your risk of prostate cancer.
Minimizing the overdiagnosis and overtreatment of localized prostate cancer is a huge challenge for both patients and health care systems. Evidence now supports the role of prebiopsy multiparametric magnetic resonance imaging (mp-MRI) as a triage tool.